
https://www.science.org/content/blog-post/beg-differ
# Beg to Differ (December 2004)

## 1. SUMMARY

This 2004 commentary responds to a reader's critique that the biotechnology/pharmaceutical industry had "lost itself to profit," with employees becoming uncreative "robots" and every decision being purely business-driven. The author sharply disputes this characterization on both fronts.

Regarding creativity and scientific engagement, the author argues that good researchers regularly encounter moments of awe at the complexity of their work, and that while some routine synthesis is necessary, a purely mechanical approach warrants replacement by automation. The author acknowledges resource constraints and pressure to produce results, but maintains that unpredictability, strange results, and breakthroughs keep scientists sharp even on main project paths.

Regarding business decisions, the author concedes that drug discovery is indeed a business, but frames this not as a corruption of science but as an essential driver that maintains a faster research pace than academia through competitive pressure—the knowledge that "other hard-hearted businesses are coming to eat our lunch" if they don't produce something marketable. This capitalist tension, while brutal, is presented as what "makes it work."

## 2. HISTORY

The biopharmaceutical landscape from 2004 to the present underwent dramatic shifts that both validated and complicated the author's defense. Key subsequent developments include:

**R&D Productivity Crisis Deepened**: The period after 2004 saw continued decline in R&D productivity, with rising drug development costs and longer timelines becoming more pronounced. The "Eroom's Law" phenomenon (Moore's Law in reverse) became widely discussed, showing that despite increased spending, the number of new drugs approved per billion dollars spent was falling.

**Industry Consolidation Accelerated**: Major mergers intensified (Pfizer-Wyeth 2009, Merck-Schering-Plough 2009, etc.), leading to larger, more bureaucratic organizations where individual creativity could indeed become more constrained. Research sites were frequently closed post-merger, and thousands of scientists lost positions.

**Academic-Industry Relationship Evolved**: While industry maintained faster project completion than academia, collaborations became more institutionalized through initiatives like the NIH's Clinical and Translational Science Awards (2006+) and industry funding of academic research centers. However, tensions over intellectual property and publication rights persisted.

**Automation and AI Reshaped Labs**: The author's suggestion that routine work should be automated proved prescient but ironic. Automated synthesis platforms and computational approaches increasingly displaced manual chemistry work, while machine learning and AI tools (accelerating especially post-2015) began transforming drug discovery. This created new types of scientific roles but reduced demand for traditional medicinal chemists performing routine synthesis.

**Clinical Success Rates Remained Low**: Despite scientific advances, clinical trial success rates for novel drugs stayed stubbornly low (10-15% from Phase I to approval), underscoring that complexity and unpredictability remained central challenges.

**Public Trust Erosion**: High-profile drug pricing controversies, opioid crisis responsibility, and concerns about data transparency damaged industry reputation, potentially validating the original commenter's cynicism about profit motives overriding scientific values.

Concrete impact: The industry continued producing important medicines (cancer immunotherapies post-2010, mRNA vaccines 2020-2021, advanced gene therapies), but structural pressures for profitability intensified, and the creative-scientific versus business-decision tension the author described became even more acute.

## 3. PREDICTIONS

The article makes several implicit predictions and arguments about industry dynamics:

• **"We know that other hard-hearted businesses are coming to eat our lunch if we don't find something that someone wants to buy"**
  - **Outcome**: Largely accurate prediction of competitive pressure. Generic competition intensified, especially after the "patent cliff" period (2010-2015) when many blockbuster drugs lost protection. Biosimilars emerged as additional competition for biologics. The rise of nimble biotech startups (often later acquired) did indeed pressure larger companies. However, the "lunch" proved more extensive than expected—established companies used aggressive lifecycle management, pricing strategies, and acquisition of innovators to maintain dominance.

• **"We don't get to discover any drugs [if we don't make money]"**
  - **Outcome**: Technically true but incomplete. The link between profitability and drug discovery remained, but the model evolved. Venture-funded biotechs increasingly conducted early discovery, with large pharma acquiring them at later stages. Debate intensified about whether profit margins (historically among the highest of any industry) exceeded levels necessary to fund innovation, particularly given massive stock buybacks and executive compensation. The fundamental capitalist logic held, but the social contract around reasonable returns became increasingly contested.

• **Implicit prediction about routine synthesis being automated**
  - **Outcome**: Materialized dramatically. Automated synthesis platforms, high-throughput experimentation, and computational chemistry tools progressively replaced manual bench chemistry for routine optimization. Companies like GSK, Pfizer and others invested heavily in automation. While this improved efficiency, it also eliminated many traditional medicinal chemistry positions, creating workforce disruption that ironically could be seen as making remaining jobs more robotic (specialized, focused on specific tasks).

• **Implicit argument that business pressure accelerates research pace vs. academia**
  - **Outcome**: Partially validated, but with nuances. Industry consistently delivered faster project completion than academic labs for applied drug development. However, academic research increasingly provided fundamental breakthroughs (CRISPR, mRNA technology, checkpoint inhibitor biology) that industry commercialized. The relationship became more symbiotic, though industry ad campaigns emphasizing their innovation role sometimes overstated actual discovery contributions. The "pace" argument held for development/clinical stages but academic basic research remained essential for entirely new therapeutic approaches.

## 4. INTEREST

Rating: **6/10**

This article captures a timeless tension in applied science—the balance between intellectual curiosity and commercial imperatives—but addresses it at a fairly general level rather than through concrete examples or novel insights. The defense of industry practices is reasonable but lacks the specificity or prescient vision that would make it highly insightful in retrospect.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20041205-beg-differ.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_